MediciNova Inc (MNOV)

Currency in USD
1.300
-0.030(-2.26%)
Real-time Data·
Advertisement
MNOV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.3001.330
52 wk Range
1.2203.900
Key Statistics
Prev. Close
1.33
Open
1.33
Day's Range
1.3-1.33
52 wk Range
1.22-3.9
Volume
1.45K
Average Volume (3m)
329.82K
1-Year Change
-9.0909%
Book Value / Share
0.83
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MNOV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8.250
Upside
+534.62%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

MediciNova Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 8.250
(+534.62% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy10.00+669.23%-Maintain29/09/2026
Roth/MKM
Buy6.00+361.54%-New Coverage17/09/2026
Maxim Group
Buy6.00+361.54%-New Coverage23/03/2026
H.C. Wainwright
Buy10.00+669.23%-New Coverage16/03/2026
Lucid Capital Markets
Buy11.00+746.15%-New Coverage05/01/2026

Earnings

Latest Release
13/11/2026
EPS / Forecast
-0.06 / -0.06
Revenue / Forecast
140K / 75K
EPS Revisions
Last 90 days

Compare MNOV to Peers and Sector

Metrics to compare
MNOV
Peers
Sector
Relationship
P/E Ratio
−6.1x9.2x−0.2x
PEG Ratio
−0.50−0.150.00
Price/Book
1.6x2.5x2.6x
Price / LTM Sales
68.6x3.8x2.7x
Upside (Analyst Target)
-72.5%69.6%
Fair Value Upside
Unlock21.9%11.7%Unlock

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.31M8.76%5.73M
Other Institutional Investors
5.47M11.11%7.28M
Public Companies & Retail Investors
39.44M80.13%52.46M
Total
49.22M100.00%65.46M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
3D Investment Partners Pte. Ltd9.88%4,862,0476,467
Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF5.37%2,644,9743,518

People Also Watch

6.280
CLRO
-8.99%
3.3700
ONCO
+6.98%
35.03
XNCR
+1.86%
36.48
PCRX
+0.05%
85.04
MMSI
-1.04%

FAQ

What Is the MediciNova (NASDAQ: MNOV) Share Price Today?

The MediciNova stock price today is 1.300 USD.

What Stock Exchange Does MediciNova (MNOV) Trade On?

MediciNova is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for MediciNova?

The stock symbol (also called a 'ticker') for MediciNova is "MNOV."

What Is the Current MediciNova Market Capitalisation?

As of today, MediciNova (NASDAQ: MNOV) market cap is 63.990M USD.

What Is MediciNova's (MNOV) Earnings Per Share (TTM)?

The MediciNova EPS is currently -0.21 (Trailing Twelve Months).

When Is the Next MediciNova Earnings Date?

MediciNova's next earnings report will be released on 19/02/2027.

Is MNOV a Buy or Sell From a Technical Analyst Perspective?

Based on today's MediciNova moving averages and other technical indicators, the daily buy/sell signal for MNOV stock is Strong Sell.

How Many Times Has MediciNova Stock Split?

MediciNova has split 0 times. (See the MNOV stock split history page for full effective split date and price information.)

How Many Employees Does MediciNova Have?

MediciNova has 6 employees, based on their latest Companies House report.

What is the current trading status of MediciNova (NASDAQ: MNOV)?

As of 19/11/2026, MediciNova (MNOV) is trading at a share price of 1.300 USD, with a previous close of 1.330 USD. The stock has fluctuated within a day range of 1.300 USD to 1.330 USD, while its 52-week range spans from 1.220 USD to 3.900 USD.

What Is MediciNova (MNOV) Price Target According to Analysts?

The average 12-month price target for MediciNova is 8.250 USD, with a high estimate of 11 USD and a low estimate of 6 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +534.62% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.